Don Rosenberg

Jan 7, 2025 | truthonthemarket.com | Eric Fruits |Don Rosenberg |Alden Abbott |Scott Lincicome

Last year, T-Mobile announced its intention to enter into a transaction with UScellular. The deal would include acquiring UScellular’s wireless operations, including its wireless customers and stores, as well as select spectrum assets. In addition, T-Mobile would enter into a long-term agreement to lease space on more than 2,000 UScellular towers.

Jan 7, 2025 | truthonthemarket.com | Don Rosenberg |Alden Abbott |Eric Fruits |Scott Lincicome

This article is a part of the Perspectives on Industrial Policy symposium. Antitrust policy in the United States generally doesn’t experience immediate dramatic revision with each new administration, and it’s unlikely that this time will be different.

Oct 14, 2024 | truthonthemarket.com | Lazar Radic |Alden Abbott |Daniel Gilman |Don Rosenberg

Inspired by the European Union’s Digital Markets Act (DMA), a growing number of jurisdictions around the globe either have adopted or are considering adopting frameworks of preemptive digital-competition rules (DCRs) that would more closely regulate the business models of such platforms as Google’s search engine and Amazon’s e-commerce business. The Turkish government may soon join them, as the draft amendment to Law No. 4054 on the Protection of Competition nears completion.

Oct 14, 2024 | truthonthemarket.com | Brian Albrecht |Daniel Gilman |Alden Abbott |Don Rosenberg

The 2024 Nobel Memorial Prize in Economic Sciences (or simply THE Nobel Prize, as I call it) was awarded this morning to Daron Acemoglu, Simon Johnson, and James Robinson “for studies of how institutions are formed and affect prosperity.” I called last year’s prize to Claudia Goldin “a surprise to no one.” This year’s prize is even less of a surprise. Acemoglu is the second-most-cited living economist.

Oct 14, 2024 | truthonthemarket.com | Alden Abbott |Daniel Gilman |Don Rosenberg

My last post highlighted a July 2024 Federal Trade Commission (FTC) interim staff report that was critical of pharmaceutical benefit managers (PBMs)—so-called “middlemen” firms that specialize in negotiating with drugmakers for rebates on the list prices of drugs. I explained that the interim report’s analysis is at odds with economic research that delineates the substantial economic benefits of the PBM system.